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Background: After hematopoietic stem cell transplantation (HSCT) T- and B-cell reconstitution from primary
lymphoid organs are a prerequisite for an effective early lymphocyte reconstitution and a long-term survival for
adult patients suffering from acute leukemia. Here, we asked whether quantification of T cell receptor excision
circle, (TREC) and kappa-deleting recombination excision circle (KREC) before and within six month after allogeneic
HSCT could be used to measure the thymic and bone marrow outputs in such patients.
Methods: We used a duplex real time PCR assay to quantify the absolute copy counts of TREC and KREC, and
correlated the data with absolute cell counts of CD3+CD4+ T-cell and CD19+ B-cell subsets determined by flow
cytometry, respectively.
Results: By comparing two recently proposed naïve T cell subsets, CD31+ naive and CD31- naive T cells, we found
a better correlation for the CD31+ subset with TREC level post alloHSCT, in line with the assumption that it
contained T cells recently derived from the thymus, indicating that TREC levels reflected real thymic de novo
production. Transitional as well as naïve B cells highly correlated with KREC levels, which suggested an association
of KREC levels with ongoing bone marrow B cell output. CD45RO+ memory T cells and CD27+ memory B cells were
significantly less correlated with TREC and KREC recovery, respectively.
Conclusion: We conclude that simultaneous TREC/ KREC quantification is as a suitable and practicable method to
monitor thymic and bone marrow output post alloHSCT in adult patients diagnosed with acute leukemia.
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Allogeneic hematopoietic stem cell transplantation
(alloHSCT) is a common treatment strategy to cure
hematological malignancies and other hematological dis-
orders [1]. Pretransplant conditioning therapy providing
space for stem cell engraftment as well as immune* Correspondence: il-kang.na@charite.de
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reproduction in any medium, provided the orsuppression therapy to prevent transplant rejection are
usually associated with a profound long-term humoral
and cellular immune deficiency [2,3]. The development of
graft-versus-host disease (GvHD) can further exacerbate
lymphocytopenia thereby increasing the risk of life-
threatening viral, bacterial and fungal infections [4,5]. T-
and B- cell reconstitution starts about 3–6 months after
alloHSCT representing a mixture of peripheral naïve and
memory cell expansion as well as de novo development
from primary lymphoid organs [2,6-9]. While expansion
of mature T and B cells will only provide a transientl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as well as potentially allo-reactive, the de novo production
from hematopoietic stem cells is important for long-term
immune protection and tolerance [2,6,7,10,11]. For indi-
vidualized monitoring of immune reconstitution in the
clinic, it is important to have validated methods to track
T- and B-cell reconstitution after alloHSCT in the relevant
patient groups.
A method to measure thymic output in the context of
aging, immunodeficiency and HSCT is the quantification
of T cell receptor excision circles (TRECs) [7,12-19].
TRECs are stable episomal, non-replicative DNA circles
generated during T cell receptor (TCR) alpha chain re-
arrangement when the excision of the D locus occurs
[20]. About 70% of all newly produced T cells are TREC
positive. TREC level are elevated in T cell preparations
of children and then decline with increasing age due to
thymic involution [12]. Nevertheless, TREC levels can
still be detected in elderly people indicating that the thy-
mus partly retains its function in old age [12,21].
In the context of HSCT, the thymus was shown to
substantially contribute to T-cell immune reconstitu-
tion after HSCT [21], and positive correlations between
TREC and total naïve CD4+ T-cell counts were assessed in
adult and pediatric alloHSCT patients [7,15,16]. Recently,
CD31 was introduced as a marker to distinguish naïve T
cells into recently thymic-derived CD4+CD31+ naïve T
cells and more mature recirculating CD4+CD31- naïve
T cells in the peripheral blood [22]. CD4+CD31+ naïve T
cells have a higher TREC content and broader TCR rep-
ertoire than CD4+CD31- naïve T cells. Clinical studies
found a positive correlation between TREC content and
frequency of CD4+CD31+ naïve T cells in adult autolo-
gous and pediatric allogeneic HSCT patients [17,19].
However, these studies did not investigate CD4+CD31-
naïve T cells, excluding the possibility of comparing the
correlation of TRECs with these two subsets of naïve T
cells in these patients. Since the regulation of CD31 ex-
pression on T cells is not known in this clinical context,
the validity of this receptor as a marker of recent thymic
emigrants after HSCT remains unresolved. Such com-
parison is also missing in adult alloHSCT patients,
which present with different clinical features than the
situations described above. Importantly, consideration
of CD31 expression as a marker for recent thymic emi-
grants needs to take into account that “old” naïve T cells
could maintain CD31 expression regardless of the time
they egressed the thymus.
It recently became possible to simultaneously measure
the thymic T- and bone marrow B-cell output using a du-
plex real-time PCR for quantification of TRECs and
κ-deleting recombination excision circles (KRECs), which
are generated during B cell development as a result of
light chain rearrangements [13,23]. Similarly to TRECs,KRECs are progressively diluted as B cells proliferate and
mature in the periphery [23]. KRECs are randomly found
in about 50% of newly produced B cells. Studies in chil-
dren post alloHSCT reported an increase in KREC level
concomitant with B cell recovery [13,18]. However, these
studies investigated total blood B cells without considering
their heterogeneity. In blood, B cells can be divided into
immature transitional B cells, which recently emigrated
from the bone marrow, naïve B cells, and memory B cells
[23]. In the context of HSCT, correlations between KREC
levels and different B cell subsets remain to be compared.
The aim of our study was to evaluate the suitability of
TREC and KREC quantification as a marker to monitor T
and B cell reconstitution in adult alloHSCT patients.
For this, we simultaneously correlated absolute TREC and
KREC copy counts with different flow cytometric deter-
mined peripheral blood T- and B-cell subsets. Here, we fo-
cused on very early time points after transplantation as an
effective lymphopoiesis during the first months after trans-
plantation was shown to be associated with improved
overall survival, thus emphasizing the importance of im-
mune monitoring during that time period [16,24].
Methods
Patients
The study included 15 adult patients diagnosed with
hematological malignancies who received full intensity
(n=8) or reduced intensity (n=7) conditioning prior to
allogeneic HSCT according to standard protocols. Clin-
ical characteristics of these patients are listed in Table 1.
The stem cells were obtained from granulocyte-colony
stimulating-factor (G-CSF) treated HLA-matched-
related (MRD, n=5) or unrelated (MRD, n=10) healthy
donors. GvHD prophylaxis included Cyclosporine A in
combination with methotrexate or mycophenolate
mofetil medication as well as ATG treatment in case of
MUD transplantation according to standard protocols.
For the kinetic study fresh patient blood samples were
obtained once before transplantation and at day 15, 30,
60, 90 and 180 post transplantation and were immedi-
ately used for analysis. The study was approved by the
Charité-Berlin local ethics committee (no. EA4/128/09
and no. EA1/233/09) and patients signed an informed
consent.
Flow cytometry analysis of lymphocyte subpopulations
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by density gradient centrifugation (Ficoll-Hypaque;
GE Healthcare) from fresh heparinized patient blood sam-
ples. After washing with PBS the cells were stained in two
staining panels for 20 min at 4°C with the following
fluorochrome-conjugated anti-human monoclonal anti-
bodies: T cell panel - CD3 APC/Cy7 (clone UCHT1), CD4
AlexaFluor 700 (clone RPA-T4), CD45RA PerCP-Cy5.5
Table 1 Clinical characteristics of alloHSCT patients
n=15 %
Median age (range) 57 (28–68)
<50 5 30
>50 10 70
Sex
female 8 53
male 7 47
Diagnosis
AML 13 87
ALL 2 13
Transplant
MUD 10 70
MRD 5 30
Conditioning
full intensity 8 53
47 reduced intensity 7 47
GvHD (acute = + Chronic)
yes 16 89
no 2 11
AML, acute myeloid leukemia; MUD, matched unrelated donor; MRD, matched
related donor; GvHD, graft-versus-host disease.
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CD62L APC (clone DREG-56), CD31 PE (clone WM59),
CD197 (CCR7) Alexa Fluor 488 (clone TG8/CCR7) from
Biolegend and CD27 PE-Cy7 (clone O323) from
eBiosciences; B cell panel - CD19 Pacific Blue (clone
HIB19), IgD-FITC (clone IA6-2), CD27 PerCP-Cy5.5
(clone O323), CD38 PE-Cy7 (clone HIT2) from Biolegend.
PBMCs were washed and analyzed by flow cytometry
using a BD™ LSRII flow cytometer (Becton Dickinson, Palo
Alto, CA, USA) supported by FlowJo 9.3 software
(TreeStar, Ashland, OR, USA).
Real-time PCR for TREC and KREC quantification
DNA was purified from PBMCs using the QIAamp DNA
Blood Mini Kit according the manufacturer’s instructions
(Qiagen, Hilden, Germany). For the simultaneous detec-
tion of TREC and KREC copy numbers a duplex Real-
Time PCR assay described by Sottini et al. [13] was
performed on the 7500 Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). Accordingly, the fol-
lowing primer and probes were used: SJ TREC forward
primer (5’-CAC ATC CCT TTC AAC CAT GCT-3’) and
reverse primer (5’-TGC AGG TGC CTA TGC ATC A-3’)
with the probe (5’-FAM-ACA CCT CTG GTT TTT GTA
AAG GTG CCC ACT TAMRA-3’) and SJ KREC forward
primer (5’-TCC CTT AGT GGC ATT ATT TGT ATC
ACT-3’) and reverse primer (5’-AGG AGC CAG CTC
TTA CCC TAG AGT-3’) with the probe (5’-HEX-TCTGCA CGG GCA GCA GGT TGG-TAMRA-3’). For the
housekeeper gene TRAC (T cell receptor alpha constant
gene) the forward primer (5’-TGG CCT AAC CCT GAT
CCT CTT-3’) and reverse primer (5’-GGA TTT AGA
GTC TCT CAG CTG GTA CAC-3’) with the probe (5’-
FAM-TCC CAC AGA TAT CCA GAA CCC TGA
CCCTAMRA- 3’) were used. PCR reactions were devel-
oped in MicroAmp®Optical 96-well reaction plates (Ap-
plied Biosystems) in a final volume of 25 μl consisting of 5
μl (100-500 ng) genomic DNA, 12.5 μl 2xTaqMan Univer-
sal PCR master mix containing AmpErase UNG (Applied
Biosystems) and primers and probes for TREC, KREC and
TRAC at a final concentration of 900 and 200 nM, re-
spectively. The PCR setup was as follows: 1x (2 min 50°C),
1x (10 min 95°C), 45x (15 sec 95°C, 1 min 60°C). TREC,
KREC and TRAC copy number were determined by ex-
trapolating the values from a unique standard curve which
was obtained by the amplification of serial dilutions of a
triple-insert plasmid (106, 105, 104, 103, 102, 101) , which
encodes one gene copy of TREC, KREC and TRAC each
[13]. The unique standard curve enabled the elimination
of variability related to direct DNA quantificaton. Assess-
ment of TRAC served as a control for the quality and
quantity of genomic DNA in the sample. The number of
TREC or KREC copies per ml blood was calculated with
the following formula:
mean KREC or TREC quantitiy
mean of TRAC quantitiy=2
 ðlymphocyte
þmonocyte countÞ=ml
The mean of TRAC quantity was divided by two con-
sidering the presence of two TRAC gene copies per cell.
True count beads (BD Biosciences) were added to whole
blood samples of patients to determine the absolute
lymphocyte and monocyte count per ml blood.
Statistics
Clinical characteristics are presented as absolute and rela-
tive frequencies. In order to account for the intra-
individual dependency over time of the TREC and KREC
data and the corresponding T and B cell subsets data, GEE
(generalized estimating equations) analyses [25] have been
performed to calculate standardized regression coefficient
betas (β) and p-values. The β coefficient measures the
strength of the effect of the respective independent vari-
able on the dependent variable that means the higher the
β, the stronger the association between the two measure-
ments. The standardized β values were used to achieve
independency of the measure units. Additionally, logarith-
mic transformations have been performed to obtain
normality. Two-sided p-values ≤ 0.05 are considered sta-
tistically significant. No Bonferroni correction has been
performed. All statistical analyses were done using the
commercially available software SPSS 20.
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Molecular and flow cytometric assessment of T and B cell
reconstitution in alloHSCT patients
Here, we simultaneously assessed the correlation between
TREC/ KREC levels and different T-/ B-cell subsets in
adult patients after alloHSCT (Table 1), with the aim to
test whether this duplex real time PCR assay could be ap-
plied for monitoring of T- and B-cell neogenesis in this
particular clinical context. This duplex PCR assay allows
the quantification of TREC and KREC in the same PCR
reaction. Thereby, naïve T and B cells emigrating from the
thymus and bone marrow, respectively, can be monitored
simultaneously without any additional expenses. Since T
and B cell maturation/differentiation are organ-specific
and exhibit individual kinetics, more information about
the immune cell reconstitution can be achieved by using
TREC and KREC.Figure 1 Flow cytometric identification of human CD3+CD4+ T- and C
quantity post alloHSCT. (A) Human peripheral blood CD3+CD4+ T-cell su
cells, CD45RA+CCR7+CD62L+CD27+CD31- naïve T cells and CD45RO+ memo
were identified by gating on IgD+CD27-CD38hi transitional B cells, IgD+CD2
are representative of a patient at day 90 post alloHSCT. Numbers indicate p
copy numbers were extrapolated from standard regression lines obtained b
plasmid encoding one copy of TREC, KREC and TRAC. Shown is one repres
linear regression line and r2 the correlation between linear regression line a
standard dilutions.Within CD3+ T cells, absolute cell counts of
CD4+CD45RA+CD31+ and CD4+CD45RA+CD31- naïve,
as well as CD4+CD45RO+ memory T cells per ml blood
were determined by flow cytometry (Figure 1A). Herein,
CD4+CD45RO+ memory T cells included CCR7+ central
memory and CCR7- effector memory T cells, but excluded
the CD4+CD45RA+CD27-CD127+ effector memory sub-
population due to a lack of CD127 in our staining. CD19+
B-cell neogenesis was analysed for the same patients by
determining absolute cell counts of IgD+CD27-CD38hi
transitional B cells, IgD+CD27-CD38int naïve B cells and
CD19+CD27+ memory B cells per ml blood (Figure 1B). In
parallel analyses, we determined absolute TREC and
KREC counts from total peripheral blood mononuclear
cells (PBMCs) as copies per ml blood. By determining the
copy number per blood volume and not per cell, we
bypassed the potential influence of peripheral proliferationD19+ B-cell subsets for correlation with absolute TREC and KREC
bsets were defined as CD45RA+CCR7+CD62L+CD27+CD31+ naïve T
ry T cell cells. (B) Within the CD19+ B cell compartment, B-cell subsets
7-CD38int naïve B cells and CD27+ memory B cells. Dotplots in A and B
ercentages of gated cell subsets. (C) Absolute TREC, KREC and TRAC
y the determination of Ct values for the serial diluted triple insert
entative standard line for each gene. m indicates the slope of the
nd obtained Ct-values as a marker for the accuracy of the respective
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of TREC, KREC and the housekeeping gene TRAC were
obtained by extrapolation from standard regression lines
determined for each gene during each qRT-PCR reaction
(Figure 1C). Standard regression lines usually were of high
quality with correlation coefficients of nearly r2=1. The
number of patient samples included in our analysis
depended on either availability of samples at defined time
points after alloHSCT or the detection limit of the TREC/
KREC assay. We included only DNA samples with a mini-
mum concentration of 50ng/ml as lower concentrations
were outside of linearity of the standard curve and there-
fore appeared not to be qualified to test reliable TREC/
KREC values. Especially during neutropenia cell numbers
were limiting.
To determine the specificity of the TREC/KREC quanti-
fication we performed the assay on genomic DNA from
the human erythroleukemia cell line K562 and from the
human T cell leukemia cell line Jurkat (Additional file 1:
Table S1). Both cell lines are negative for TREC [27,28]
and KREC probably due to clonal proliferation, but posi-
tive for TRAC. Accordingly, we found an amplification of
TRAC but no off-target amplification of TREC and KREC
on these cell lines Genomic DNA from PBMCs of a
healthy donor served as a positive control.TREC and T cell subset recovery after alloHSCT
Absolute cell counts of CD4+CD45RA+CD31+ naïve,
CD4+CD45RA+CD31- naïve and CD4+CD45RO+ mem-
ory T cells were determined by flow cytometry before and
within six month after transplantation. Absolute numbers
of CD4+CD45RA+CD31+ and CD4+CD45RA+CD31- naïve
T cells were characterized by slow reconstitution kinetics,
which started to increase on day 30, and remained below
pre-transplant level until day 180 (mean 130±32 cells/ml
and 49±15 cells/ml, respectively) (Figure 2A,C). The
strongest expansion was seen for memory T cells that
reached pre-transplant levels (mean 186±20 cells/ml)
already on day 30, and then increased further (589±196
cells/ml on day 180) (Figure 2E). Such initial expansion of
memory T cells within the first six months post alloHSCT
was similarly described in previous publications and was
shown to represent antigen-driven immune activation
with increased susceptibility to activation-induced cell
death of alloreactive donor-derived memory T cells [15].
In parallel analyses, we determined absolute TREC
counts from total peripheral blood mononuclear cells
(PBMCs) as copies per ml blood. TRECs drastically de-
clined after transplantation before recovering around
day 180 (Figure 2A,C,E). At day 180, TRECs were still
below the pretransplant level (mean 1285±634 copies/
ml). TREC values of 2306 copies per ml were reported
for healthy controls [14].After having quantified amounts of distinct T cell subsets
and TRECs at various time points after alloHSCT, we then
tested the possible correlation between these parameters
(Figure 2B,D,F). We determined standardized β-values by
perfoming GEE analyses that account for longitudinal, i.e.
intraindividually dependent data. Since in our study we
consider the entire information of all measurement time
points, the GEE analysis is most appropriate to model the
longitudinal character of the data accurately. In contrast to
these point estimates usual linear regression models would
have been underestimated and thus been too optimistically.
We observed that in line with previous publications,
TREC recovery correlated with the numbers of both,
CD4+CD45RA+CD31+ and CD4+CD45RA+CD31- naïve T
cells [7,15,17,19]. A better correlation was observed for
CD4+CD45RA+CD31+ (Figure 2B) than for CD4+CD45RA
+CD31- (Figure 2D) naïve T cells (ß = 0.518, p < 0.01 for
CD4+CD45RA+CD31+ naïve; ß = 0.470, p < 0.05 for
CD4+CD45RA+CD31- naïve). This is consistent with the
notion that CD4+CD45RA+CD31+ naïve T cells are more
likely recent thymic emigrants, while CD4+CD45RA
+CD31- naïve T cells contain more mature cells that resided
in the periphery for longer times and proliferated [22], even
though this had not been tested so far in the context of
alloHSCT. Lymphocytopenia after conditioning therapy and
T cell-depletion drives cell proliferation in the “empty” host
especially within the first weeks post transplantation when
IL-7 serum levels are increased, leading to a subsequent loss
of TRECs [15,29]. However, the existence of “old” naïve T
cells with maintained CD31 expression can not be excluded,
so that CD31 expression does not necessarily represent an
exclusive marker for T cells that recently emigrated from
the thymus. [30] The poorest correlation was found for the
CD4+CD45RO+ memory T cell subset (Figure 2F) (ß =
0.339, p < 0.05). This is in line with observations made in
healthy individuals, whose memory T cells exhibited a ten-
fold lower TREC content than naïve T cells [31].
Immune reconstitution differs in patients receiving full-
conditioning and reduced-intensity conditioning therapy.
For example, depending on the level of toxicity variable
damage/ destruction of the bone marrow niche or thymus
as well as of the host hematopoietic cell compartment oc-
curs. Consequently, bone marrow and thymus output is
more impaired after high-intensity conditioning therapy,
whereas expansion of host T cells contributes more to the
T cell repertoire after reduced-intensity conditioning ther-
apy. We therefore separated patients receiving either full-
conditioning or reduced-conditioning, and could still ob-
serve that TREC levels correlated with CD31+ naïve CD4
T cells (Additional file 2: Figure S1A).
More patients, preferably independent groups of pa-
tients, are required to estimate significant differences of
β values between each of these T cell subsets and in de-
pendency on different clinical parameters, which should
Figure 2 Correlation analysis of TREC quantification with T-cell subset recovery after alloHSCT. (A,C,E) PBMCs of adult alloHSCT patients
were analyzed for absolute CD4+CD3+ T-cell subset counts by flow cytometry and absolute TREC copy number by quantitative RT-PCR before
(preTx) and after transplantation at the indicated time points (preTx n=7, D15 n=11, D30 n=13, D60 n=8, D90 n=13, D180 n=8). Mean values of
TREC copy number per ml blood (grey line, A,C,E) and absolute number of CD31+ naive (A), CD31- naïve (C) and memory T cells (E) per ml
blood (black line) ± standard error of the mean (SEM) are shown. (B,D,F) Absolute TREC copy number and T-cell subset count are shown as
scatterplot depiction with linear regression line for CD31+ naive (B), CD31- naïve (D) and memory T cells (F). The regression coefficients beta (β*)
and p-values are displayed for each subpopulation.
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this assay.
Recently, protein tyrosine kinase 7 (PTK7) as a novel
marker for human CD4+ recent thymic emigrants and
the assay to determine the sj-TREC / β-TREC ratio for
thymic function assessment have been introduced
[27,32]. PTK7+ naïve CD4+ recent thymic emigrants
contain a higher level of TRECs, are more responsive to
interleukin 7 and rapidly decrease after thymectomy.
Although promising, this marker has not been applied
in the setting of HSCT. Interestingly, expression of
PTK7 was also found on AML blasts [33], so value
of PTK7 as a recent thymic emigrant marker posttransplantation in AML patient should be evaluated
[27]. The sj-TREC / β-TREC ratio reflects the intensity
of proliferation between DβJβ rearrangement and the
VαJα rearrangement, which in turn is the major deter-
minant of the number of recent thymic emigrants pro-
duced. The major advantages of this technology are
independence of peripheral proliferation, measurement
of thymic neogenesis of all αβ-T cells independent of
their phenotype and gain of information about T cell re-
ceptor diversity [32]. However, this powerful method-
ology is, in contrast to the duplex PCR assay presented
here, labor intensive, even in the simplified approach
presented by Ferrando-Martinez et al. [34].
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Equivalently, we determined absolute cell counts of
IgD+CD27-CD38hi transitional, IgD+CD27-CD38int naïve
and CD27+ memory B cells as well as absolute KREC copy
numbers per ml blood before and within six months after
transplantation. After transplantation, the number of B
cells increased, beginning with memory B cells on day
30 (Figure 3E), transitional B cells on day 60 (Figure 3A),
and naïve B cells on day 90 (Figure 3C), but numbers
of transitional and naïve B cells remained below
pretransplant levels until day 180 (mean 12±10 cells/ml
and 63±52 cells/ml, respectively).
Interestingly, already at the pretransplant period we
observed a very low number of KRECs with 2331±1155
copies per ml of blood, while a KREC value of 14846
copies per ml was reported for healthy controlsFigure 3 Correlation analysis of KREC quantification with B-cell subse
counts of IgD+CD27-CD38hi transitional B, IgD+CD27-CD38int naïve B and C
and after transplantation (preTx: n=7, D15 n=11, D30 n=13, D60 n=8, D90 n
and absolute number of transitional (A), naïve (C) and memory B cells (E)
Absolute KREC copy number and B-cell subset count are depicted as scatte
memory B cells (F). The regression coefficients beta (β*) and p-values are d(Figure 3A,C,E) [14]. In contrast to TRECs that dropped
from higher pretransplant to low posttransplant levels,
KRECs only slightly decreased upon transplantation.
KRECs started to increase on day 60, and were fivefold
higher on day 180 compared to pretransplant level,
reaching values of 10809±4510 copies/ml. KREC recovery
showed a good and statistically significant correlation with
both transitional and naïve B-cell recovery, whereas
memory B cells correlated less (Figure 3B,D,F) (ß = 0.585,
p < 0.001 transitional; ß = 0.663, p < 0.001 naïve;
ß = 0.383, p < 0.05 memory). B cells typically undergo sev-
eral rounds of cell division during their differentiation into
memory cells [23]. Therefore, a low contribution to the
KREC pool and consequently less correlation of memory
B cells with KRECs was expected. When separating the
patients into a full-conditioning and reduced-conditioningt recovery after alloHSCT. (A,C,E) Absolute CD19+ B-cell subset
D27+ memory B cells and KREC copy number were determined before
=12, D180 n =9). KREC copy number per ml blood (grey line, A,C,E)
per ml blood (black line) are shown as mean values ± SEM. (B,D,F)
rplots with linear regression line for transitional (B), naïve (D) and
isplayed for each subpopulation.
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with transitional B cells (Additional file 2: Figure S1B).
Like for TREC, larger patients cohorts would allow to de-
termine significant differences in ß values for different B
cell subsets and different clinical settings.
We further compared the obtained TREC/ KREC values
with patients total white blood cell count as measured at
each time point in the hospital setting (Additional file 3:
Figure S2). TREC as well as KREC kinetics clearly differed
from the leukocyte kinetics showing no congruent course
of TREC/KREC recovery with leukocyte recovery after
alloHSCT. This suggests the TREC/KREC assay to provide
useful additional information for monitoring the dynamics
of immune system reconstitution after alloHSCT and
therefore may have clinical utility. In particular, the duplex
PCR presented here is a time- and laboratory costs-saving
assay that allows simultaneous quantification of TREC
and KREC in only one PCR reaction. TREC/KREC levels
are normalized to the quantity of genomic DNA in the
sample and variability related to direct DNA quantification
is eliminated by using a unique standard curve and TREC/
KREC quantification per ml of blood overcomes the issue
of peripheral dilution. However, we are aware of the fact,
that the measurements alone cannot be considered as dir-
ect markers for clinical episodes, because TREC/ KREC
can persist in old emigrant cells and disappear after cell
death. This easy performable assay rather represents a
first-step screening that needs be tested in a larger patient
cohort in correlation to clinical parameters, and also
should be combined with other methods to help defining
the reasons for low TREC/ KREC levels.
Conclusion
In summary, our study suggests that the combined quanti-
fication of absolute TREC and KREC counts is a suitable
marker to monitor early T- and B-cell neogenesis in adult
patients treated by alloHSCT for hematological malignan-
cies. Both markers exhibited kinetics best comparable with
the most primitive T/B cell phenotypes, CD4+CD45RA
+CD31+ naïve T-cell as well as transitional (IgD+CD27-
CD38hi) and naïve (IgD+CD27-CD38int) B-cell reconstitu-
tion, respectively, allowing an estimate of thymic and bone
marrow output post alloHSCT. Having validated good
correlations, relationship of TREC/ KREC levels and
thereby thymic and bone marrow function should be
tested next in correlation to clinical episodes such as
GvHD, graft failure or Cytomegalovirus and Epstein-Barr
virus reactivation in a considerably larger patient cohort
allowing multivariate analyses and corrections for co-
nfounding effects due to clinical heterogeneity. In case of
good correlations with these clinical parameters, TREC
and KREC enumeration could be used in combination
with T- and B-cell subset quantification in routine clinical
monitoring to optimize personalized treatment strategies.For TREC and KREC quantification, low associated re-
agent costs, DNA stability as well as the need of only
small blood volumes would be advantageous especially
during lymphocytopenia during the first months after
transplantation.
Additional files
Additional file 1: Table S1. Specificity controls for the TREC/ KREC
quantification assay.
Additional file 2: Figure S1. TREC/ KREC level correlation with naïve
CD4+ T cells/ transitional B cells in patients with full or reduced intensity
conditioning therapy. (A) Absolute CD4+CD45RA+CD31+ naïve T cell
and TREC copy numbers before and after transplantation are shown for
patients who received full-conditioning (left) or reduced-conditioning
(right) therapy (full-conditioning/reduced conditioning: preTx n=5/2, D15
n=6/5, D30 n=8/5, D60 n=5/3, D90 n=6/7, D180 n=3/5). (B) Graphs show
absolute transitional B-cell and KREC copy numbers in patients who
underwent full-conditioning (left) or reduced-conditioning (right) therapy
(full-conditioning/reduced conditioning: preTx: n=5/2, D15 n=6/5, D30
n=8/5, D60 n=6/2, D90 n=6/6, D180 n =3/6). TREC/ KREC copy numbers
(grey line) and T-/ B-cell subset number (black line) are displayed as
mean values ± SEM.
Additional file 3: Figure S2. Incongruent course of absolute TREC or
KREC copy counts and leukocyte recovery after alloHSCT. (A,B) Absolute
leukocyte counts were obtained from hospital measurements before and
after transplantation (preTx: n=6, D15 n=9, D30 n=11, D60 n=8, D90
n=11, D180 n =4). Shown are mean values ± SEM of TREC (A) or KREC
(B) copy number per ml blood (grey line) and leukocyte count per ml
blood (black line, A,B).
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